StemCell InstituteTSE:7096 +0.92%69 Net Margin % is 5.09% as of Mar. 2026, which is 46% below its 10-year median of 9.47. GuruFocus rates TSE:7096 with a GF Score™ of 69/100 and a GF Value™ of 円1,813.82 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 941 Biotechnology companies, StemCell Institute ranks better than 76.51% on this metric.
The historical rank and industry rank for StemCell Institute's Net Margin % or its related term are showing as below:
TSE:7096'
s Net Margin % Range Over the Past 10 Years
Min: 4.42 Med: 9.47 Max: 16.55
Current: 5.55
TSE:7096's Net Margin % is ranked better than 76.51% of 941
companies
in the Biotechnology industry
Industry Median: -88.29
vs TSE:7096: 5.55
StemCell Institute (TSE:7096) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
StemCell Institute Net Margin % Related Terms
StemCell Institute Net Margin % Historical Data
* Premium members only.
The historical data trend for StemCell Institute's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:7096 vs VRTX, REGN, ALNY: Net Margin % Comparison
For the Biotechnology subindustry, StemCell Institute's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
StemCell Institute Net Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, StemCell Institute's Net Margin % distribution charts can be found below:
* The bar in red indicates where StemCell Institute's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
StemCell Institute (TSE:7096) has a Net Margin % of 5.09% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on StemCell Institute and its competitors. This is 46% below median its historical median of 9.47. Over the past decade, StemCell Institute's Net Margin % has ranged from 4.42 to 16.55. According to the industry distribution chart, StemCell Institute ranks #221 out of 941 companies in the Biotechnology industry, placing it in the top 23.5%.
Is StemCell Institute's Net Margin % too high?
StemCell Institute's current Net Margin % of 5.09% is 46% below median its 10-year median of 9.47. Over the past 10 years, this metric has ranged from a low of 4.42 to a high of 16.55. Based on the distribution chart, StemCell Institute ranks #221 out of 941 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, StemCell Institute has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does StemCell Institute's Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, StemCell Institute ranks #221 out of 941 companies for Net Margin %. This places StemCell Institute in the top 24% of its industry — outperforming the majority of peers. Historically, StemCell Institute's own Net Margin % has ranged from 4.42 to 16.55 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on StemCell Institute and its competitors. StemCell Institute's current Net Margin % is 5.09%, which is 46% below median its own 10-year median of 9.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is StemCell Institute stock overvalued right now?
Based on GuruFocus' analysis, StemCell Institute (TSE:7096) is currently considered Possible Value Trap. The stock's GF Value™ is 円1,813.82, compared to a current price of 円768.00 — trading 57.7% below its estimated fair value. The current Net Margin % is 5.09%, which is 46% below median its 10-year median of 9.47. StemCell Institute's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For StemCell Institute (TSE:7096), the current Net Margin % is 5.09% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is StemCell Institute (TSE:7096) Overvalued in 2026?
Based on GuruFocus' analysis, StemCell Institute stock appears to be undervalued.
The current stock price of 円768.00 is trading 57.7% below its estimated GF Value™ of 円1,813.82.
GuruFocus considers StemCell Institute to be Possible Value Trap.
Key valuation signals for TSE:7096:
Net Margin %: 5.09% (46% below median its 10-year median of 9.47)
GF Value™: 円1,813.82 vs. price of 円768.00 (57.7% below fair value)
No single metric tells the full story. See the TSE:7096 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
StemCell Institute is engaged in the Cell bank business that separates and stores cord blood for regenerative medicine. Cord blood is the baby's blood contained in the umbilical cord and placenta that connects the mother and baby. In its umbilical cord blood storage business, upon receiving notification from customers who have contracted, umbilical cord blood collected at obstetric facilities throughout Japan is collected, transported to the company's cell processing center within 48 hours, and it provides a service to store cells at ultra-low temperature after separating cells from blood. The Company operates in a single segment, the cell bank business sales consist of three components: technical fees, storage fees, and other fees.
69GF Score
Get the complete analysis for TSE:7096
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:7096 has been successfully added to your 
